GHENT, Belgium, 20 January 2014 - Ablynx [Euronext Brussels: ABLX] today
announced, in conformity with Title II of the Law of 2 May 2007 and the Royal
Decree of 14 February 2008, that an additional 5,583 common shares have been
issued by the Company in exchange for â‚¬27,440.04 as the result of the exercise
of warrants by some employees and consultants of the Company.
As a result of this transaction, Ablynx now has 48,998,229 shares outstanding.
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(Â®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 30 programmes in the pipeline and seven Nanobodies in clinical
development. Ablynx has on-going research collaborations and significant
partnerships with major pharmaceutical companies including AbbVie, Boehringer
Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is
headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more information, please contact Ablynx:
Dr Edwin Moses
t:Â Â +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
Â Â Â Â +32 (0)473 39 50 68
Associate Director Investor Relations
t:Â Â +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t:Â Â +44 207 920 2345
eÂ : firstname.lastname@example.org
Pdf version of the press release:
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via GlobeNewswire